Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xoma has expanded its efforts to discover, develop and manufacture therapeutic antibodies and other proteins for the US government.
Subscribe to our email newsletter
In 2005, Xoma entered into a $15 million contract with the National Institute of Allergy and Infectious Diseases (NIAID) to develop cell lines, optimize production processes and manufacture three antibodies against botulinum neurotoxin in support of the US’ biodefense efforts.
“Since we began our contract with NIAID, it has become clear that Xoma’s capabilities have many more applications in government service, particularly with our national emphasis on biodefense,” said Jack Castello, Xoma’s chairman, president and CEO.
The company also said that Dr Patrick Scannon is to lead the project. Dr Scannon founded Xoma in 1980 and has been a member of the company’s executive team and board of directors since that time. In his new role, Dr Scannon will serve as Xoma’s chief liaison with the government agencies, whilst also continuing to oversee trials of the company’s Neuprex product.